SolnCell™
Cell Screening Platform
SolnCell™
Cell Screening Platform
Data-Empowered Cell Therapy Development.
Defining New Standards through Evidence-Based Screening.
Integrating high-throughput screening with multi-omics data analysis, SolnCell™ constructs a comprehensive stem cell functional map, predicting differentiation potential, tumorigenic risk, and in vivo efficacy. Backed by tens of millions of real-world data points, the platform reduces R&D timelines by 40% and doubles success rates.
-
High-Efficiency Screening
Automated culture combined with intelligent recognition processes tens of thousands of cell samples daily. -
Multi-Omics Integration
Integrates transcriptomic, proteomic, and metabolomic data to construct a comprehensive cell functional landscape. -
Intelligent Prediction
Predicts differentiation potential, tumorigenic risk, in vivo homing efficiency, and persistence. -
Data Scale
Tens of millions of real-world data points accumulated, covering MSC, TSPC, iPSC, NK, and other cell types. -
Efficiency Leap
R&D timelines reduced by 40%; clinical translation success rates doubled. -
Standard Leadership
Core participant in the development of industry standards including the Clinical Application Guidelines for Tendon Stem Cells.
SolnCell™
Cell Screening Platform
SolnCell™
Cell Screening Platform
Data-Empowered Cell Therapy Development.
Defining New Standards through Evidence-Based Screening.
Integrating high-throughput screening with multi-omics data analysis, SolnCell™ constructs a comprehensive stem cell functional map, predicting differentiation potential, tumorigenic risk, and in vivo efficacy. Backed by tens of millions of real-world data points, the platform reduces R&D timelines by 40% and doubles success rates.
-
High-Efficiency Screening
Automated culture combined with intelligent recognition processes tens of thousands of cell samples daily. -
Multi-Omics Integration
Integrates transcriptomic, proteomic, and metabolomic data to construct a comprehensive cell functional landscape. -
Intelligent Prediction
Predicts differentiation potential, tumorigenic risk, in vivo homing efficiency, and persistence. -
Data Scale
Tens of millions of real-world data points accumulated, covering MSC, TSPC, iPSC, NK, and other cell types. -
Efficiency Leap
R&D timelines reduced by 40%; clinical translation success rates doubled. -
Standard Leadership
Core participant in the development of industry standards including the Clinical Application Guidelines for Tendon Stem Cells.
Regenerative Medicine Cell Therapy Pipeline
Candidate |
Indication |
Drug Design & Screening |
CMC/IIT |
IND |
Phase I/II/III |
NDA |
Commercial Rights |
|---|---|---|---|---|---|---|---|
| SunRay001 > | |||||||
| SunRay001Key Component | Tendon Stem/Progenitor Cells (TSPC) | Rotator Cuff Tear, Achilles Tendon Injury, Tendinopathy |
|
 |
||||
SUNRAY R&D Pipeline
SunRay001
-
SunRay001
Allogeneic Tendon Stem Cell Injection (TSPC)
An allogeneic tendon stem/progenitor cell (TSPC) formulation administered via ultrasound-guided local injection, capable of differentiating into tenocytes and secreting extracellular matrix to achieve functional tendon regeneration.
Mechanism of Action
Stem cells home to the injury site, differentiate into tenocytes, secrete extracellular matrix, and reconstruct the tendon microstructure, enabling scarless functional healing.
Unmet Need
Post-surgical retear rates range from 20% to 94%; current therapies fail to restore native tendon function, leaving patients facing repeated surgeries and loss of motor capacity.
Current Status
China's first tendon stem cell IIT clinical trial has been approved and initiated at the Second Affiliated Hospital of Zhejiang University, with follow-up expected to complete by the end of 2026; the world's first serum-free medium specifically developed for tendon stem cells has been successfully developed in parallel.